

**AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—COCATS 4 TASK FORCE 12: TRAINING IN HEART FAILURE**

<b>Committee Member</b>	<b>Employment</b>	<b>Consultant</b>	<b>Speaker's Bureau</b>	<b>Ownership/ Partnership/ Principal</b>	<b>Personal Research</b>	<b>Institutional/ Organizational or Other Financial Benefit</b>	<b>Expert Witness</b>
Mariell Jessup <i>(Chair)</i>	University of Pennsylvania School of Medicine—Professor of Medicine	None	None	None	<ul style="list-style-type: none"> <li>• Amgen*‡</li> <li>• HeartWare*‡</li> </ul>	<ul style="list-style-type: none"> <li>• American Heart Association*</li> </ul>	None
Reza Ardehali	University of California Los Angeles—Assistant Professor of Medicine (Cardiology)	None	None	None	<ul style="list-style-type: none"> <li>• NIH*</li> </ul>	None	None
Marvin A. Konstam	Tufts University School of Medicine—Professor; Director, Cardiovascular Center	<ul style="list-style-type: none"> <li>• Amgen†</li> <li>• Boehringer Ingelheim†</li> <li>• Bristol-Myers Squibb</li> <li>• Cardiokine</li> <li>• CardioMEMS</li> <li>• Cardioxyl</li> <li>• Daiichi-Sankyo†</li> <li>• Harvest</li> <li>• Johnson &amp; Johnson†</li> <li>• Merck</li> <li>• Novartis</li> <li>• Ono</li> <li>• Otsuka†</li> <li>• Pharmaceuticals</li> <li>• Sanofi-aventis</li> </ul>	None	None	None	None	None
Bruno V. Manno	Pennsylvania Heart and Vascular Group, P.C.—Cardiologist	None	None	None	None	None	None
Michael A. Mathier	University of Pittsburgh Medical Center Heart and Vascular Institute—Assistant Professor of Medicine; Associate Director, Cardiovascular Fellowship Program	None	None	None	None	None	None
John A. McPherson	Vanderbilt University School of Medicine—Associate Professor of Medicine; Vice-Chair for Education, Department of Medicine	<ul style="list-style-type: none"> <li>• CardioDx</li> <li>• Healthwise</li> <li>• Velomedix</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Abbott†</li> <li>• CardioDx</li> <li>• NIH/NHLBI†</li> </ul>	None	None
Nancy K. Sweitzer	Sarver Heart Center University of Arizona—Director; Professor; Chief,	<ul style="list-style-type: none"> <li>• Heart Genomics</li> <li>• Novartis</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• NIH†</li> <li>• NIH*</li> </ul>	None	None

<b>Committee Member</b>	<b>Employment</b>	<b>Consultant</b>	<b>Speaker's Bureau</b>	<b>Ownership/ Partnership/ Principal</b>	<b>Personal Research</b>	<b>Institutional/ Organizational or Other Financial Benefit</b>	<b>Expert Witness</b>
	Division of Cardiology				• University of Arizona†		

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$10,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

\*No financial benefit.

†Significant relationship.

‡Discontinued in April 2012.

NHLBI = National Heart, Lung, and Blood Institute; NIH = National Institutes of Health.